Characterization of a chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor, of topoisomerase II

Biochemical Pharmacology

Volumn 53, Issue 12, 1997, Pages 1843-1853

  Hasinoff, Brian B ^a   Kuschak, Theodore I ^a   Creighton, Andrew M ^c   Fattman, Cheryl L ^b   Allan, William P ^b   Thampatty, Padmakumari ^b   Yalowich, Jack C ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bisdioxopiperazine; Dexrazoxane; ICRF 193; ICRF 187; Resistant cell; Topoisomerase II

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; RAZOXANE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHO CELL; CROSS RESISTANCE; CULTURE MEDIUM; CYTOTOXICITY; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ACLARUBICIN; ANIMALS; CHO CELLS; CRICETINAE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE; ETHYLENEDIAMINES; ETOPOSIDE; GLYCINE; MUTATION; RAZOXANE; THIOBARBITURATES; VERAPAMIL;

EID: 0030739460     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00013-0     Document Type: Article

References (47)

1. Ishida R, Miki T, Narica T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T, Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909-4916, 1991.
2. Hasinoff BB, Kuschak TI, Yalowich JC and Creighton AM, A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50: 953-958, 1995.
3. Ohno R, Yamada K, Hirano M, Shirakawa S, Tanaka M, Oguri T, Kodera Y, Mitomo Y, Ikeda Y, Yokomaku S, Kamiya O, Kobayashi M, Saito H and Kimura K, Phase II study: Treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine). J Natl Cancer Inst 84: 435-438, 1992.
4. Roca J, Ishida R, Berger JM, Andoh T and Wang JC, Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781-1785, 1994.
5. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E and Demant EJF, Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46: 389-393, 1993.
6. Creighton AM, Hellmann K and Whitecross S, Antitumour activity in a series of bisdiketopiperazines. Nature 22: 384-385, 1969.
7. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, Attubato M, Burrows W and Muggia FM, ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10: 117-127, 1992.
8. Hasinoff BB, Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci 83: 64-67, 1994.
9. Buss JL and Hasinoff BB, The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40: 86-95, 1993.
10. Corbett AH and Osheroff N, When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by anti-neoplastic drugs. Chem Res Toxicol 6: 585-597, 1993.
11. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A and Larsen AK, Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 89: 3025-3029, 1992.
12. Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR and Mirabelli CK, In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578-2583, 1989.
13. Jensen PB, Jensen PS, Demant EJF, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindelov L, Westergaard O and Hansen HH, Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: Relationship to DNA integrity and topoisomerase II. Cancer Res 51: 5093-5099, 1991.
14. Fattman C, Allan WP, Hasinoff BB and Yalowich JC, Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem Pharmacol 52: 635-642, 1996.
15. Hasinoff BB, Yalowich JC, Ling Y and Buss JL, The effect of dexrazoxane (ICRF-187) on doxorubicin and daunorubicin-mediated growth inhibition of Chinese hamster ovary (CHO) cells. Anticancer Drugs 7: 558-567, 1996.
16. Sehested M and Jensen PB, Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51: 879-886, 1996.
17. Creighton AM, Piperazine derivatives. U.K. Patent 1,234,935, 1971.
18. Creighton AM, 3,5-Dioxopiperazine derivatives. U.K. Patent 1,374,979, 1974.
19. Ritke MK, Allan WP, Fattman C, Gunduz NN and Yalowich JC, Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 46: 58-66, 1994.
20. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV and Yalowich JC, Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. Br J Cancer 69: 687-697, 1994.
21. Sahai BM and Kaplan JG, A quantitative decatenation assay for type II topoisomerases. Anal Biochem 156: 364-379, 1986.
22. Huang Z-X, May PM, Quinlan KM, Williams DR and Creighton AM, Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12: 536-542, 1982.
23. Tanabe K, Ikegami Y, Ishida R and Andoh T, Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903-4908, 1991.
24. Kenwrick SJ, Studies on the mechanism of induced resistance to antitumour agent ICRF 159 in mammalian cell lines. Ph.D. Thesis, University of London, London, 1984.
25. Jensen PB, Sorensen BS, Sehested M, Demant EJF, Kjeldsen E, Friche E and Hansen HH, Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45: 2025-2035, 1993.
26. Pommier Y, DNA topoisomerases and their inhibition by anthracyclines. In: Anthracycline Antiobiotics, New Analogues, Methods of Delivery, and Mechanisms of Action (Ed. Priebe W), pp. 183-203. American Chemical Society, Washington, DC, 1995.
27. Osheroff N, Corbett AH, Elsea SH and Westergaard M, Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes. Cancer Chemother Pharmacol 34 (Suppl): S19-S25, 1994.
28. Froelich-Ammon SJ and Osheroff N, Topoisomerase poisons: Harnessing the dark side of enzyme mechanism. J Biol Chem 270: 21429-21432, 1995.
29. Cobb PW, Degen DR, Clark GM, Chen SF, Kuhn JG, Gross JL, Kirshenbaum MR, Sun JH, Burris HA 3rd and Von Hoff DD, Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units. J Natl Cancer Inst 86: 1462-1465, 1994.
30. Roberge M, Tudan V, Hung SMF, Harder KW, Jirik FR and Anderson H, Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 54: 6115-6121, 1994.
31. Beck WT, Danks MK, Yalowich JC, Zamora JM and Cirtain MC, Different mechanisms of multiple drug resistance. In: Mechanisms of Drug Resistance in Neoplastic Cells (Eds. Woolley PV and Tew KD), pp. 212-222. Academic Press, San Diego, 1988.
32. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC and Andoh T, DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299-2303, 1995.
33. Roca J and Wang JC, The capture of a DNA double helix by an ATP-dependent protein clamp: A key step in DNA transport by type II DNA topoisomerases. Cell 71: 833-840, 1992.
34. Wasserman RA and Wang JC, Mechanistic studies of amsacrine-resistant derivatives of DNA topisomerase II. J Biol Chem 269: 20943-20951, 1994.
35. Chen AY and Liu LF, Mechanisms of resistance to topoisomerase inhibitors. In: Anticancer Drug Resistance: Advances in Molecular and Clinical Research (Eds. Goldstein LJ and Ozols RF), pp. 263-281. Kluwer, Dordrecht, 1994.
36. Beck WT, Danks MK, Wolverton JS, Chen M, Granzen B, Kim R and Suttle DP, Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol Chemother 29B: 145-170, 1994.
37. Harker WG, Slade DL, Parr RL and Holguin MH, Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase IIα. Cancer Res 55: 4962-4971, 1995.
38. Feldhoff PW, Mirski SEL, Cole SPC and Sullivan DM, Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 54: 756-762, 1994.
39. Lautier D, Canitrot Y, Deeley RG and Cole SPC, Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977, 1996.
40. Chen M and Beck WT, DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol Res 7: 103-111, 1995.
41. Ganapathi R, Constantinou A, Kamath N, Dubyak G, Grabowski D and Krivacic K, Resistance to etoposide in human leukemia HL-60 cells: Reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol Pharmacol 50: 243-248, 1996.
42. Takano H, Kohno K, Ono M, Uchida Y and Kuwano M, Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951-3957, 1991.
43. Lelievre S, Benchokroun Y and Larsen AK, Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Mol Pharmacol 47: 898-906, 1995.
44. Kenwrick SJ and Creighton AM, Isolation and characterization of a subline of CHO cells with induced resistance to ICRF 159. Br J Cancer 46: 504-505, 1982.
45. Sehested M, Holm B, Kenwrick S and Creighton AM, CHO cells resistant to the topoisomerase II catalytic inhibitor ICRF-159 have altered drug-DNA-enzyme binding capability. Proc Am Assoc Cancer Res 37: 436, 1996.
46. White K and Creighton AM, Mechanistic studies with a cell line resistant to ICRF-159. Br J Cancer 34: 323, 1976.
47. White K, Studies on the mechanism of cellular resistance to the antitumor agent ICRF 159. Ph.D. Thesis, University of London, London, 1978.